China Atherosclerosis Therapeutics Market Analysis

China Atherosclerosis Therapeutics Market Analysis


$ 3999

China Atherosclerosis Therapeutics Market was valued at $225 Mn in 2022 and is estimated to reach $393 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., China Resources Pharmaceutical Group, Huahai Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Qilu Pharmaceutical Co. and Yisheng Pharmaceutical Co.

ID: IN10CNPH434 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Medha Sansanwal

Buy Now

China Atherosclerosis Therapeutics Market Executive Summary

China Atherosclerosis Therapeutics Market was valued at $225 Mn in 2022 and is estimated to reach $393 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period.

Atherosclerosis causes plaque, a sticky material consisting of calcium, fat, cholesterol, and other components, to accumulate inside the walls of arteries. This buildup increases the risk of serious illnesses such as heart attacks and strokes, which cause blood vessels to narrow or get blocked. Numerous variables, including high blood pressure, high cholesterol, diabetes, obesity, smoking, a family history of heart disease, inactivity, and an unhealthy diet, can lead to atherosclerosis. Numerous medications, including statins, aspirin, and beta-blockers, have demonstrated potential in reducing or halting the progression of atherosclerosis.

The prevalence of carotid atherosclerosis in China, an indicator of atherosclerosis, is 21.0% for carotid plaque, 0.56% for carotid stenosis, and 26.2% for increased intima-media thickness. Gender and age have an impact, with men typically having a larger prevalence than women and higher rates among older persons. Geographically, because risk factors are concentrated in metropolitan areas, prevalence is higher in urban areas. In China, atherosclerosis plays a major role in cardiovascular diseases (CVD), which account for about half of all deaths and include peripheral artery disease, ischemic heart disease, and stroke. Cardiovascular illnesses have a significant financial cost that affects healthcare systems and productivity.

The Phase IIb clinical trial for HMPL-523, an innovative oral CETP inhibitor intended to reduce cardiovascular risk, is presently being advanced by Hutchison MediPharma. Cholesteryl Ester Transfer Protein, or CETP, is essential for lipid metabolism. As a first-in-class inhibitor, HMPL-523 has the potential to entirely alter the approach by which cardiovascular disease is treated. An important step forward in the development of innovative therapeutics for cardiovascular disorders is being made with the ongoing trial, which aims to assess the safety and effectiveness of HMPL-523 in lowering cardiovascular risk.

A Phase II clinical trial has been started by Innovent Therapeutics for IBI-346, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) demonstrating potential. IBI-346 targets PCSK9, a protein known for its function in controlling cholesterol levels, and is specially designed to treat hyperlipidemia and atherosclerosis.

China Atherosclerosis Therapeutics Market Analysis 2022 to 2030

Market Dynamics

Market Growth Drivers

Rising Prevalence of Cardiovascular Disease (CVD): With the largest population in the world, China is dealing with 330 Mn people who suffer from CVD, with atherosclerosis being the main cause of these instances. Rapid urbanization and changes in lifestyle patterns, such as unhealthy eating habits, smoking, and sedentary activity, have been strongly linked to the rise in CVD cases.

Aging Population: The rapidly aging population in China is a major driver of market expansion in the atherosclerosis drug treatment industry. Age-related increases in atherosclerosis susceptibility increase demand for medications that address this problem. According to projections, over 25% of China's population is expected to be over 65 by 2030, which will increase demand for atherosclerosis treatment medications and support the market's growth.

Rising Awareness and Early Diagnosis: As a result of improved screening methods and heightened public awareness of cardiovascular health, atherosclerosis is discovered early, encouraging people to seek treatment sooner rather than later. This early intervention is likely to drive greater demand for medication throughout patient's lives.

Market Restraints

High Cost of Treatment: Accessibility may be limited by the high price of innovative and effective atherosclerosis drugs, especially the most recent biologics. This problem is made more acute in rural areas where access to healthcare is restricted for a significant proportion of the population due to limited insurance coverage and tight healthcare expenditures. A large segment of the population faces accessibility issues because of the high cost of atherosclerosis drug treatment, which operates as a market restraint in China. This is particularly true for rural areas where healthcare budgets and insurance coverage are constrained.

Lack of Awareness and Early Diagnosis: Atherosclerosis and the associated risk factors are not commonly understood among the Chinese community, which could lead to a delayed diagnosis and missed opportunities for early management. Due to this lack of knowledge, the potential market size for opportunities in initial treatment is reduced, which serves as a market restraint.

Compliance and Adherence Issues: Long-term drug adherence is often required for the treatment of atherosclerosis, which can be challenging for some patients who experience adverse effects, forgetfulness, or low motivation. The complexity of managing multiple medications for various health conditions further exacerbates challenges in adherence. The need for long-term medication adherence, along with difficulties like side effects and the difficulty of managing multiple medications, may discourage patient compliance, limiting the market potential for treatment solutions. This presents a market restraint for the atherosclerosis therapeutics market.

Healthcare Policies and Regulatory Landscape

Treatment drug regulations in China are governed by the China National Medical Products Administration (NMPA), which has a thorough drug approval procedure that includes preclinical research, clinical trials, and post-marketing surveillance. The National Healthcare Security Administration (NHSA) decides on reimbursement guidelines and negotiates medication costs with pharmaceutical companies. Strengthening intellectual property protection in the pharmaceutical industry and increasing the coverage of health insurance are two other key objectives of China's healthcare policies.

Competitive Landscape

Key Players

  • Pfizer
  • Novartis
  • AstraZeneca
  • Sanofi
  • Merck & Co.
  • China Resources Pharmaceutical Group
  • Huahai Pharmaceutical Group
  • Jiangsu Hengrui Medicine Co.
  • Qilu Pharmaceutical Co.
  • Yisheng Pharmaceutical Co.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Atherosclerosis Therapeutics Market Segmentation

By Therapy

  • Atherosclerosis Medications
  • Cholesterol-lowering Medications
  • Antiplatelet drugs and Anticoagulants
  • Atherosclerosis Beta Blockers
  • Diuretics or Water Pills
  • Angiotensin Converting Enzyme (Ace) Inhibitors
  • Other Atherosclerosis Treatment Therapies

By Surgery

  • Bypass Surgery (Coronary Artery Bypass Grafting (CABG))
  • Angioplasty
  • Atherectomy

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Manufactured Combination

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Clinics
  • Drug stores
  • Retail pharmacies
  • Online pharmacies
  • Other distribution channel

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 06 March 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up